{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T13:48:24Z","timestamp":1771595304370,"version":"3.50.1"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.10743","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T15:33:36Z","timestamp":1651851216000},"page":"e2210743","source":"Crossref","is-referenced-by-count":30,"title":["Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State\u2013wide Psychiatric Hospital System"],"prefix":"10.1001","volume":"5","author":[{"given":"Katlyn","family":"Nemani","sequence":"first","affiliation":[{"name":"Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York"},{"name":"Department of Psychiatry, New York University Langone Medical Center, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharifa Z.","family":"Williams","sequence":"additional","affiliation":[{"name":"Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Olfson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Columbia University Irving Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Leckman-Westin","sequence":"additional","affiliation":[{"name":"New York State Office of Mental Health, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Finnerty","sequence":"additional","affiliation":[{"name":"New York State Office of Mental Health, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jammie","family":"Kammer","sequence":"additional","affiliation":[{"name":"New York State Office of Mental Health, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Smith","sequence":"additional","affiliation":[{"name":"New York State Office of Mental Health, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Silverman","sequence":"additional","affiliation":[{"name":"New York State Office of Mental Health, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Lindenmayer","sequence":"additional","affiliation":[{"name":"Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York"},{"name":"Department of Psychiatry, New York University Langone Medical Center, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Capichioni","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University Langone Medical Center, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Clelland","sequence":"additional","affiliation":[{"name":"Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald C.","family":"Goff","sequence":"additional","affiliation":[{"name":"Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York"},{"name":"Department of Psychiatry, New York University Langone Medical Center, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"issue":"9","key":"zoi220321r1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S2215-0366(21)00232-7","article-title":"Mental disorders and risk of COVID-19\u2013related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis.","volume":"8","author":"Vai","year":"2021","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"zoi220321r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.23282","article-title":"Association of a prior psychiatric diagnosis with mortality among hospitalized patients with coronavirus disease 2019 (COVID-19) infection.","volume":"3","author":"Li","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"11","key":"zoi220321r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.34969","article-title":"Analysis of COVID-19 infection and mortality among patients with psychiatric disorders, 2020.","volume":"4","author":"Teixeira","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi220321r4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/wps.v20.1","article-title":"Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States.","volume":"20","author":"Wang","year":"2021","journal-title":"World Psychiatry"},{"issue":"11","key":"zoi220321r5","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1001\/jamapsychiatry.2021.2274","article-title":"Association between mental health disorders and mortality among patients with COVID-19 in 7 countries: a systematic review and meta-analysis.","volume":"78","author":"Fond","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"zoi220321r6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jamapsychiatry.2020.4442","article-title":"Association of psychiatric disorders with mortality among patients with COVID-19.","volume":"78","author":"Nemani","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"zoi220321r7","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/schbul\/sbab012","article-title":"COVID-19 prevalence and mortality among schizophrenia patients: a large-scale retrospective cohort study.","volume":"47","author":"Tzur Bitan","year":"2021","journal-title":"Schizophr Bull"},{"issue":"9","key":"zoi220321r8","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamapsychiatry.2020.0894","article-title":"Addressing the COVID-19 pandemic in populations with serious mental illness.","volume":"77","author":"Druss","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"zoi220321r9","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1001\/jamapsychiatry.2021.2503","article-title":"Association between antipsychotic use and COVID-19 mortality among people with serious mental illness.","volume":"78","author":"Nemani","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"zoi220321r10","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe9403","author":"Gordon","year":"2020","journal-title":"Science"},{"issue":"3","key":"zoi220321r11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.encep.2020.05.006","article-title":"Repurposing chlorpromazine to treat COVID-19: the reCoVery study.","volume":"46","author":"Plaze","year":"2020","journal-title":"Encephale"},{"key":"zoi220321r12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.652688","article-title":"Fluvoxamine: a review of its mechanism of action and its role in COVID-19.","volume":"12","author":"Sukhatme","year":"2021","journal-title":"Front Pharmacol"},{"key":"zoi220321r13","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00448-4","article-title":"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.","author":"Reis","year":"2022","journal-title":"Lancet Glob Health"},{"issue":"11","key":"zoi220321r14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.33090","article-title":"Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants.","volume":"4","author":"Oskotsky","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi220321r15","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.1038\/s41380-021-01021-4","article-title":"Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study.","volume":"26","author":"Hoertel","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"2","key":"zoi220321r16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247122","article-title":"Observational study of haloperidol in hospitalized patients with COVID-19.","volume":"16","author":"Hoertel","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"zoi220321r17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40261-021-01001-0","article-title":"Observational study of chlorpromazine in hospitalized patients with COVID-19.","volume":"41","author":"Hoertel","year":"2021","journal-title":"Clin Drug Investig"},{"key":"zoi220321r18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.schres.2022.01.035","article-title":"Olanzapine, risperidone and quetiapine: do these atypical antipsychotics have a protective effect for SARS-CoV-2?","volume":"241","author":"Prokopez","year":"2022","journal-title":"Schizophr Res"},{"issue":"12","key":"zoi220321r19","doi-asserted-by":"publisher","first-page":"7093","DOI":"10.1038\/s41380-021-01222-x","article-title":"Diversity of mechanism of action of psychotropic drugs in their anti-COVID-19 properties.","volume":"26","author":"Stip","year":"2021","journal-title":"Mol Psychiatry"},{"key":"zoi220321r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104663","article-title":"Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect.","volume":"133","author":"Maine","year":"2020","journal-title":"J Clin Virol"},{"issue":"2","key":"zoi220321r23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1473-3099(20)30769-6","article-title":"Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis.","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"25","key":"zoi220321r24","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1056\/NEJMc2029354","article-title":"Risk factors for SARS-CoV-2 in a statewide correctional system.","volume":"383","author":"Kennedy","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"zoi220321r25","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMoa2005412","article-title":"Epidemiology of Covid-19 in a long-term care facility in King County, Washington.","volume":"382","author":"McMichael","year":"2020","journal-title":"N Engl J Med"},{"issue":"17","key":"zoi220321r26","doi-asserted-by":"publisher","first-page":"6772","DOI":"10.1080\/07391102.2020.1802346","article-title":"In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials.","volume":"39","author":"Gul","year":"2021","journal-title":"J Biomol Struct Dyn"},{"issue":"5","key":"zoi220321r27","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.psym.2020.05.025","article-title":"Clozapine toxicity in the setting of COVID-19.","volume":"61","author":"Dotson","year":"2020","journal-title":"Psychosomatics"},{"issue":"1","key":"zoi220321r28","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1192\/bjp.2020.151","article-title":"Clozapine treatment and risk of COVID-19 infection: retrospective cohort study.","volume":"219","author":"Govind","year":"2021","journal-title":"Br J Psychiatry"},{"key":"zoi220321r29","author":"Okusaga","year":"2021","journal-title":"J Clin Psychiatry"},{"key":"zoi220321r30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.schres.2021.06.019","article-title":"An analysis of the possible protective effect of antipsychotics for SARS-CoV-2 in patients under treatment for severe mental illnesses.","volume":"233","author":"Prokopez","year":"2021","journal-title":"Schizophr Res"},{"key":"zoi220321r31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/978-3-030-39141-6","article-title":"Inflammation, antipsychotic drugs, and evidence for effectiveness of anti-inflammatory agents in schizophrenia.","volume":"44","author":"Pandurangi","year":"2020","journal-title":"Curr Top Behav Neurosci"},{"key":"zoi220321r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.173988","article-title":"Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19.","volume":"898","author":"Pitt","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"zoi220321r33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.23937\/2378-3516","article-title":"Valproic acid in prevention and treatment of COVID-19.","volume":"7","author":"Singh","year":"2020","journal-title":"Int J Respir Pulm Med"},{"issue":"3","key":"zoi220321r34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2174\/1389450121666201020154033","article-title":"Downregulation of membrane-bound angiotensin converting enzyme 2 (ACE2) receptor has a pivotal role in COVID-19 immunopathology.","volume":"22","author":"Vieira","year":"2021","journal-title":"Curr Drug Targets"},{"issue":"6","key":"zoi220321r35","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1002\/cpt.v110.6","article-title":"Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for severe COVID-19: an observational multicenter study.","volume":"110","author":"Hoertel","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"zoi220321r36","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.2105\/AJPH.2021.306444","article-title":"COVID-19 case rates after surveillance and vaccinations in a statewide psychiatric hospital system.","volume":"111","author":"Smith","year":"2021","journal-title":"Am J Public Health"},{"key":"zoi220321r22","doi-asserted-by":"crossref","DOI":"10.1002\/9781118548387","volume-title":"Applied Logistic Regression","author":"Hosmer","year":"2013","edition":"3rd ed"},{"key":"zoi220321r20","unstructured":"US Food and Drug Administration. EUA authorized serology test performance. Accessed October 3, 2021. https:\/\/www.fda.gov\/medical-devices\/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices\/eua-authorized-serology-test-performance"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2791969\/nemani_2022_oi_220321_1651174051.2345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T15:33:40Z","timestamp":1651851220000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2791969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.10743","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,6]]}}}